Biointron Biological

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. From gene sequence to purified antibodies, our production only takes 2 weeks — and with RushData, our AI antibody wet lab validation service, computational predictions become experimentally confirmed candidates at high throughput. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization for global biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide.

We provide antibody discovery, expression and optimization services, including VHH antibody discovery, single B-cell antibody screening, hybridoma sequencing, antibody humanization, antibody affinity maturation, and RushData (an AI antibody wet lab validation service that provides high-throughput wet lab validation for AI/ML-designed antibody candidates, turning computational predictions into experimentally confirmed data).

Additionally, Biointron holds global sublicensing rights for ECACC's CHO-K1. Our CHOK1BN cell line, which is derived from CHO-K1, has been filed in the DMF system with the US FDA. By choosing the CHOK1BN cell line, several partners' projects have entered multicenter international clinical trials successfully. 

For more information, please visit our official website: www.biointron.com, or contact: [email protected]

• Immunology/inflammation
• Platform Technology
• Antibodies
• Oncology